Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...
7News Miami9h
HHS invests nearly $600 million in Moderna’s bird flu vaccine development
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...
Moderna Faces Uncertainty Amidst Strategic Efforts and Competitive Challenges
J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...
health.wusf.usf.edu9h
U.S. pays $590 million to Moderna to speed up development of bird flu vaccine
The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top ...
Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%
Shares of Moderna dropped more than 20% intraday to $33.44, more than erasing gains last week after the first bird-flu death ...
Moderna Faces Financial Uncertainty Amid Market Competition and Revenue Challenges
Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...
TMCnet5d
Ex-Deep Genomics, Moderna Execs Get Backing Led by Gradient to Develop Next-Generation mRNA Therapeutics with AI
With a mission to expand mRNA's therapeutic possibilities, Kerna Labs is pushing the boundaries of what's possible in genetic medicine. "We're on the cusp of a major leap forward in genetic medicine, ...
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...
The State6d
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Moderna and Merck rapidly expanded clinical studies to additional tumor types and the Phase 3 clinical trial for adjuvant melanoma completed enrollment in 2024. Rare disease therapeutics ...